False-Positive Elevation of Creatine Kinase MB Mass Concentrations Caused by Macromolecules in a Patient who Underwent Nephrectomy for Renal Cell Carcinoma

Uğur

et al. 2019

VHRM

308

204

PurposeAcute myocardial infarction (AMI) is the most common cause of death in the world. Comprehensive risk assessment of patients presenting with chest pain and eliminating undesirable results should decrease morbidity and mortality rates, increase the quality of life of patients, and decrease health expenditure in many countries. In this study, the advantages and disadvantages of the enzymatic and nonenzymatic biomarkers used in the diagnosis of patients with AMI are given in historical sequence, and some candidate biomarkers – hFABP, GPBB, S100, PAPP-A, RP, TNF, IL6, IL18, CD40 ligand, MPO, MMP9, cell-adhesion molecules, oxidized LDL, glutathione, homocysteine, fibrinogen, and D-dimer procalcitonin – with a possible role in the diagnosis of AMI are discussed.MethodsThe present study was carried out using meta-analyses, reviews of clinical trials, evidence-based medicine, and guidelines indexed in PubMed and Web of Science.ResultsThese numerous AMI biomarkers guide clinical applications (diagnostic methods, risk stratification, and treatment). Today, however, TnI remains the gold standard for the diagnosis of AMI. Details in the text will be given of many biomarkers for the diagnosis of AMI.ConclusionWe evaluated the advantages and disadvantages of routine enzymatic and nonenzymatic biomarkers and the literature evidence of other candidate biomarkers in the diagnosis of AMI, and discuss challenges and constraints that limit translational use from bench to bedside.

Section: Resultsmentioning

confidence: 99%

<p>Biomarkers in acute myocardial infarction: current perspectives</p>

Uğur

et al. 2019

VHRM

308

204

Front. Cardiovasc. Med.

“…CK-MB activity has been recognized as a specific and sensitive biomarker of clinical and subclinical myocardial injury ( 8 , 18 ). CK-MB activities are significantly positively correlated with the extent of myocardial injury, so serum CK-MB can be used as a biomarker for AMI ( 19 ). The presence of CK-MB in patients with cancers may cause confusion with AMI.…”

Section: Discussionmentioning

confidence: 99%

Use of Anti-angiogenic Drugs Potentially Associated With an Increase on Serum AST, LDH, CK, and CK-MB Activities in Patients With Cancer: A Retrospective Study

Zheng

Wang

Hou

et al. 2021

Background: There is a large amount of evidence that anti-angiogenic drugs are effective safe. However, few studies have evaluated the specific effects of anti-angiogenic drugs on myocardial enzyme injury biomarkers: aspartate aminotransferase (AST), lactic dehydrogenase (LDH), creatine kinase (CK) and creatine kinase isoenzyme (CK-MB). The purpose of our study was to determine whether anti-angiogenic drugs serum AST, LDH, CK, and CK-MB activities of cancer patients treated with anti-angiogenic drugs.Methods: This study retrospectively analyzed 81 cancer patients. Patients who had used anti-angiogenic drugs were selected. Serum AST, LDH, CK, and CK-MB activities were measured before and after treatment with anti-angiogenic drugs for 3 weeks.Results: A total of 16 cancer types were analyzed. The distribution of the cancer types in the patients was mainly concentrated in lung, gastric, and colorectal cancers. The anti-angiogenic treatment markedly increased AST, LDH, CK, and CK-MB activities by 32.51, 7.29, 31.25, and 55.56%, respectively in serum.Conclusions: Our findings suggest that patients, who had used anti-angiogenic drugs were likely to have elevated AST, LDH, and CK, indicators of myocardial muscle injury. Use of anti-angiogenic drugs should not be assumed to be completely safe and without any cardiovascular risks.

“…In 1970 radioimmunoassay was discovered [12], and the measurement of CK activity is a more accurate predictor of myocardial infarction. Damage has been a crucial diagnostic factor for the diagnosis of AMI for the last 20 years [13]. Similar to myoglobin, the CK enzyme is the first biomarker to increase.…”

Section: Creatine Kinase (Ck)mentioning

confidence: 99%

Interpreting Myocardial Enzymatic Biomarkers in the Setting of Acute Myocardial Infraction AMI

Kasar

Al-Bahrani

Mohsin

2022

The rates of morbidity and mortality for acute myocardial infarction (AMI) have been rising quickly in the last few years. In the systemic circulatory loop, the heart normally pumps blood to the body's extremities. Cardiovascular disease, however, results from any heart function problem. The most fatal diseases in the world are known to be those involving the cardiovascular system. Over the past decade, biochemical marker testing are an important step in the diagnosis, and management of heart failure and in lowering one's risk of developing cardiovascular disease. Early diagnosis is paramount to choosing a clear and effective treatment strategy. Cardiac biomarkers are another effective method for classifying myocardial injury. The myocardial enzymatic biomarkers, also known as myocardial necrosis biomarkers, were among the various biomarkers that were initially studied. This review aims to allow for appropriate management steps to be initiated and more efficient and effective utilization of healthcare resources.